skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Measured dose to ovaries and testes from Hodgkin's fields and determination of genetically significant dose

Abstract

The purpose of this study was to determine the genetically significant dose from therapeutic radiation exposure with Hodgkin's fields by estimating the doses to ovaries and testes. Phantom measurements were performed to verify estimated doses to ovaries and testes from Hodgkin's fields. Thermoluminescent LiF dosimeters (TLD-100) of 1 x 3 x 3 mm[sup 3] dimensions were embedded in phantoms and exposed to standard mantle and paraaortic fields using Co-60, 4 MV, 6 MV, and 10 MV photon beams. The results show that measured doses to ovaries and testes are about two to five times higher than the corresponding graphically estimated doses for Co-60 and 4 MVX photon beams as depicted in ICRP publication 44. In addition, the measured doses to ovaries and testes are about 30% to 65% lower for 10 MV photon beams than for their corresponding Co-60 photon beams. The genetically significant dose from Hodgkin's treatment (less than 0.01 mSv) adds about 4% to the genetically significant dose contribution to medical procedures and adds less than 1% to the genetically significant dose from all sources. Therefore, the consequence to society is considered to be very small. The consequences for the individual patient are, likewise, small. 28 refs., 3more » figs., 5 tabs.« less

Authors:
;  [1]
  1. (Georgetown Univ. Medical Center, Washington, DC (United States))
Publication Date:
OSTI Identifier:
6790128
Alternate Identifier(s):
OSTI ID: 6790128
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; (United States); Journal Volume: 25:4
Country of Publication:
United States
Language:
English
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; HODGKINS DISEASE; RADIOTHERAPY; OVARIES; GENETICALLY SIGNIFICANT DOSE; SIDE EFFECTS; TESTES; BODY; DISEASES; DOSES; FEMALE GENITALS; GONADS; IMMUNE SYSTEM DISEASES; LYMPHOMAS; MALE GENITALS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIATION DOSES; RADIOLOGY; THERAPY 560151* -- Radiation Effects on Animals-- Man

Citation Formats

Niroomand-Rad, A., and Cumberlin, R.. Measured dose to ovaries and testes from Hodgkin's fields and determination of genetically significant dose. United States: N. p., 1993. Web. doi:10.1016/0360-3016(93)90023-O.
Niroomand-Rad, A., & Cumberlin, R.. Measured dose to ovaries and testes from Hodgkin's fields and determination of genetically significant dose. United States. doi:10.1016/0360-3016(93)90023-O.
Niroomand-Rad, A., and Cumberlin, R.. Mon . "Measured dose to ovaries and testes from Hodgkin's fields and determination of genetically significant dose". United States. doi:10.1016/0360-3016(93)90023-O.
@article{osti_6790128,
title = {Measured dose to ovaries and testes from Hodgkin's fields and determination of genetically significant dose},
author = {Niroomand-Rad, A. and Cumberlin, R.},
abstractNote = {The purpose of this study was to determine the genetically significant dose from therapeutic radiation exposure with Hodgkin's fields by estimating the doses to ovaries and testes. Phantom measurements were performed to verify estimated doses to ovaries and testes from Hodgkin's fields. Thermoluminescent LiF dosimeters (TLD-100) of 1 x 3 x 3 mm[sup 3] dimensions were embedded in phantoms and exposed to standard mantle and paraaortic fields using Co-60, 4 MV, 6 MV, and 10 MV photon beams. The results show that measured doses to ovaries and testes are about two to five times higher than the corresponding graphically estimated doses for Co-60 and 4 MVX photon beams as depicted in ICRP publication 44. In addition, the measured doses to ovaries and testes are about 30% to 65% lower for 10 MV photon beams than for their corresponding Co-60 photon beams. The genetically significant dose from Hodgkin's treatment (less than 0.01 mSv) adds about 4% to the genetically significant dose contribution to medical procedures and adds less than 1% to the genetically significant dose from all sources. Therefore, the consequence to society is considered to be very small. The consequences for the individual patient are, likewise, small. 28 refs., 3 figs., 5 tabs.},
doi = {10.1016/0360-3016(93)90023-O},
journal = {International Journal of Radiation Oncology, Biology and Physics; (United States)},
number = ,
volume = 25:4,
place = {United States},
year = {Mon Mar 15 00:00:00 EST 1993},
month = {Mon Mar 15 00:00:00 EST 1993}
}